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Abstract: A successful prostate cancer must be capable of changing its phenotype in response to a
variety of microenvironmental influences, such as adaptation to treatment or successful proliferation
at a particular metastatic site. New cell phenotypes emerge by selection from the large, genotypically
heterogeneous pool of candidate cells present within any tumor mass, including a distinct stem
cell-like population. In such a multicellular model of human prostate cancer, flexible responses are
primarily governed not only by de novo mutations but appear to be dominated by a combination of
epigenetic controls, whose application results in treatment resistance and tumor relapse. Detailed
studies of these individual cell populations have resulted in an epigenetic model for epithelial cell
differentiation, which is also instructive in explaining the reported high and inevitable relapse rates
of human prostate cancers to a multitude of treatment types.
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1. Introduction: Prostate Cancer Is a Heterogeneous Disease Governed by Episodic
Genomic Rearrangements
Human prostate cancer has a deserved reputation for being amongst the most heterogeneous
of human tumors [1]. Heterogeneity is reflected at the level of (i) gene expression, where not all
the cells within a cancer mass express tumor markers to the same extent, (ii) at the genetic level,
where multiple genomic rearrangements are present within the same mass of tumor and ultimately
(iii) in patient response to common therapies, where tumors with an identical pathology show widely
diverse responses to standard chemotherapy treatments. For example, fewer than 50% percent of
cancers show a positive response to standard of care treatment such as docetaxel, despite all tumors
containing replicating cells which microtubule poisons such as Docetaxel should be able to affect [2].
Whilst such heterogeneity is generally accepted, it is rarely reflected in molecular studies of the
cancers, either at the phenotypic or genotypic levels [3–5]. The effects of heterogeneity have been
previously discussed in some detail [1], but the many different cell types in a “tumor” include variable
proportions of stromal (connective tissue) cells which we and others have shown to play a significant
etiological role in the gene expression within the epithelial component of the cancer [6–8], but also
minor cell populations, as a result of lymphocytic or macrophage infiltration, the proportion of which
is variable within the tumors, and has been shown to influence/treatment responses and hence patient
outcomes [9].
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The current approach to tumor heterogeneity, deep sequencing of genomic DNA, has identified a
degree of genomic and clonal variations, and increasing levels of mutations between treatment naïve
tumors [10] and aggressive castration-resistant disease (CRPC) [11], which develops after the failure
of androgen receptor inhibition therapies [12,13]. However, all of these studies are limited by the
resolution and error rates of the sequencing procedures, to probably 90% i.e., a population of less
than 10% within the tumor mass, is likely to be either overlooked or could fail to reach statistical
significance [14]. A second historical limitation of these high resolution studies has been the need for
relatively large amounts of DNA to carry out reproducible sequencing in the absence of G+C bias
introduced by the need for PCR amplification at a sufficient depth of read to pick out rare populations,
limiting the starting materials (such as those available in the online databases such as TCGA) to
an analysis of larger tumors: imposing a selection for growth and often greater heterogeneity [15].
The ability to sequence single cell genomes should resolve this, but studies in other tumors [16,17]
frequently turn up “novel” cell types. It is tempting to reject cells which do not fit an existing hypothesis,
on the basis that they do not conform to an existing cancer phenotype [18], such as a luminal phenotype
in prostate cancer.
In contrast to tumors where there is a known chemical etiological agent (e.g., components of
cigarette smoke in bronchial carcinoma), prostate cancers have a relatively low rate of single base pair
changes within the tumor mass [19]. In fact, most prostate cancers are characterized by episodic and
catastrophic rearrangements of the genome, which include chromosomal translocations and segmental
deletions [20]. The induction of such changes has been linked to androgen regulation via a number of
different effector genes including the SPOP ubiquitin ligase [21,22].
Gene expression patterns are equally heterogeneous in both normal and malignant prostate glands
where, as a cell becomes more defined, gene expression is not only more restricted, but is considerably
enhanced. For example, the expression of genes for proteins secreted by the non-dividing, terminally
differentiated prostatic luminal cells (e.g., polyamines and kallikreins) is governed by promoters whose
activity is many thousand-fold higher than those of maintenance genes such as those required in basal
cells (Figure 1). Some malignancy signatures more closely related to “immunity genes” may reflect
lymphocytic infiltration levels whilst measurements of presumably tumor-derived RNAs in serum
display virtually no identity in the diagnostic gene panels between duplicate studies of the same
patient blood samples in different laboratories [23,24].
Even in human tissues where great care has been taken to micro-dissect the epithelial component,
there remains a gross element of heterogeneity according to the basal or luminal origin of the epithelial
cells. In normal prostate, the luminal epithelial fraction comprises around 50% of the cellular epithelial
population, whereas basal epithelial cells form the remainder within a gland. In cancers, this ratio
is extremely skewed: more than 99% of the cancer mass is a luminal-like cell, which is incompletely
differentiated (whilst expressing androgen receptor and prostate-specific antigen) but has gained the
ability to replicate in an uncontrolled fashion. However, within the tumor mass, there also remains
a small population (fewer than 1% of cells) with a basal-like phenotype [1]. To resolve such minor
populations requires an approach pioneered by John Dick and colleagues for live cell fractionation of
Acute Myeloid Leukemias [25]. Given the complexities of cell phenotypes (see below) such approaches
are at best high enrichments rather than purifications, but by analyzing the transcriptomes of the
different populations the true phenotypes of minor populations can be derived and linked to function
(see Figure 2).
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Figure 1. Cell phenotypes and the epigenetic landscape of normal human prostate epithelium (A)
Epithelial Cell populations in a normal prostate, with the stem cell at the upper apex. It is important
to note that the distinct cell types shown are simply representative and that the situation in a real
tissue is much more plastic. Only the stem cell and the terminally differentiated luminal cell have
truly defined phenotypes. The remaining cells are part of a continuum of change. Various antigenic
markers used to enrich for or identify cell populations are shown in the extreme right column.
(B) Waddington’s epigenetic landscape (after Waddington 1940). The model emphasizes the continuum
of the differentiation process. The ultimate fate of a cell is to migrate to the base of the slope, as fully
differentiated luminal and neuroendocrine cells. The reversibility of the differentiation continuum, to a
stem cell fate from fully differentiated cells, requires “energy” or multiple gene mutations/activations
to promote a cell “upwards” to the stem cell (SC) state.
Figure 2. Cont.
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Figure 2. Strategies to categorize the genes and miRNAs which modulate prostate epithelial
differentiation. (A) mRNA co-expression analysis in the transition from SC to CB (committed basal)
cells in human prostate epithelial cells [26]. Clustering reveals gene pairs which always change together,
in this transition and in other cell systems. Note the lack of overlap between the various gene clusters,
implying a common control system for each cluster. Selected individual genes are listed in Tables 1 and 2.
Identification of individual genes is possible by zooming in electronically on the figure. (B) miRNA
expression datasets were generated from different cell populations from prostate tissues with a variety
of pathologies [27]. Unsupervised clustering of the miRNA database indicated that miRNA expression
was more closely correlated to differentiation that normal/benign/cancer tissues. Note (lower right
panel) the high expression of miRNA (warm color) in the SC, which decays in the TA population,
with increasing downregulation (shown as blue) as the cells become more differentiated (CB cells) and
begin to express a wider and more specialized mRNA set. (C) Gene ontology strategy to relate miRNA
expression to that of mRNA known to be expressed in the various prostate epithelial cell types [28].
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Table 1. Co-regulated gene clusters during prostate epithelial cell differentiation.
Gene Group Common Gene Ontology Terms Selected Members
A None
PSEN1
ITGB6
IRF6
B Cell cycleChromatin condensation
CDCA2
TOP2A
CDC20
C Epidermal differentiationEndopeptidase activity
TMPRSS2
S100P
SPINK7
ELF3
LXN
MSMB
D (Lens) Epithelial development CTNNB1IGFR2
Co-regulated genes expressed as discrete non-overlapping clusters (Figure 2A) during prostate epithelial cell
differentiation. Data from Reference [26].
Table 2. Major transcription factors implicated in prostate epithelial cell differentiation.
TF Identity Full Name Principal Role
RXR
Retinoid X receptor: acts as a homodimer or as a heterodimer
with other receptors (e.g., VDR). Binds co-repressors of
transcription (as a repressor) until a conformation change
occurs after ligand binding.
Reproduction, cellular differentiation, bone development,
haematopoiesis and pattern formation during embryogenesis
VDR
Vitamin D Receptor: homodimer in the absence of ligand then
heterodimerises with RXR to increase transcription of a
number of genes. Interacts with SMAD3 and MED1, NCOA1,
NCOA2, NCOA3 and NCOA6 coactivators.
Mineral metabolism (calcium homeostasis) although VDR
regulates a variety of other pathways, such as those involved
in the immune response and cancer. Keratinocyte, mammary
and prostate differentiation.
GCR
Glucocorticoid Receptor (N3CR1): acts both as a transcription
factor and modulator of other transcription factors by binding
to glucocorticoid response elements (GRE), both in the cell
nucleus and mitochondria.
Affects inflammatory responses, cellular proliferation and
differentiation in target tissues. Also involved in chromatin
remodeling and RNA stability/degradation.
TAZ
Transcriptional co-activator with PDZ-binding motif (or
WWTR1): acts as a transcriptional co-activator, downstream of
the Hippo pathway. Regulated by soluble extra-cellular
factors, cell–cell adhesions and mechano-transduction.
Interacts with and regulates multiple transcription factors, e.g.,
Runx2 PPAR TBX5, TBX5, TEADs, TTF-1 and PAX3.
Organ development, stem cell differentiation and
development of human cancer. Mesenchymal stem cell
differentiation, promoting cell proliferation and
epithelial-mesenchymal transition (EMT). TAZ senses different
cellular signals such as cell density and the extracellular
matrix stiffness. Significantly overexpressed in breast cancer
samples and papillary thyroid carcinoma tissues.
SRF
Serum Response Factor: member of the MADS box
superfamily of transcription factors, and binds to the serum
response element (SRE) in the promoter region of target genes.
SRF regulates the activity of many immediate-early genes, e.g.,
c-fos. A downstream target of many pathways; for example,
the mitogen-activated protein kinase pathway (MAPK).
Stimulates cell cycle regulation, apoptosis, cell growth,
and cell differentiation.
In embryonic development, Expression controls the formation
of mesoderm and is crucial for the growth of skeletal muscle.
Interaction of SRF with other proteins, such as steroid
hormone receptors, may contribute to the regulation of muscle
growth by steroids.
HSF1
Heat shock transcription factor 1: an inactive monomer in a
complex with Hsp40/Hsp70 and Hsp90. Target genes include
major inducible heat shock proteins such as Hsp72 and
noncoding RNA within Satellite III repeat regions. Upon
stress, such as elevated temperature, HSF1 is released from the
chaperone complex and trimerizes. HSF1 is then transported
into the nucleus where it is hyperphosphorylated and binds to
heat shock elements in DNA.
Master regulator of stress responses, mammalian
development, insulin metabolism, cell division, transcriptional
reprogramming/chromatin status.
ROCK2
Rho-associated coiled coil-containing protein kinase 2:
regulates smooth muscle contraction, actin cytoskeleton
organization, stress fiber and focal adhesion formation, neurite
retraction, cell adhesion and motility via phosphorylation of
ADD1, BRCA2, CNN1, EZR, DPYSL2, EP300, MSN,
MYL9/MLC2, NPM1, RDX, PPP1R12A and VIM.
Phosphorylates SORL1 and IRF4. Acts as a negative regulator
of VEGF-induced angiogenic endothelial cell activation and
inhibits keratinocyte terminal differentiation.
Regulates cytoplasmic actin and cell polarity. Major regulator
of epithelial terminal differentiation.
Major transcriptional effectors of the stem cell state identified in promoter analyses of differentially regulated genes
matched to their known expression levels in prostate epithelial stem cells. Data from Reference [26].
Int. J. Mol. Sci. 2019, 20, 2437 6 of 31
Others have reported similar cell fractionation protocols, which indicated that a basal cell was the
likely origin for the most aggressive and malignant prostate cancers. A human basal cell of origin [29–31]
is more likely (but as yet unproven) than the luminal precursor predicted from mouse experiments [32].
To generate the predominantly luminal phenotype of prostate cancers, such a basal origin implies that
the initiating cell population must both differentiate and expand. Until recently, the factors which
control both normal and aberrant differentiation in prostate epithelium were unknown.
2. Stem Cell Versus Stochastic Mechanisms of Cancer Induction
The cell of origin (COO) of prostate cancer has been briefly discussed above. Logically, given the
time required to develop a cancer, the COO should be long-lived in order to accumulate necessary
changes. The slow turnover of prostate stem cells can also explain the slow progression and late-onset
of prostate cancer (reviewed in [1]). Mathematical modelling by Tomasetti and Vogelstein [33] more
recently sought to establish a positive correlation between the number of stem cell divisions and
the incidence/age of onset of cancer in more rapidly renewing tissues such as the colon. Obligatory
carcinogenic changes in pre-cancer [34] should include the loss of normal microenvironmental control
(aberrant growth), although activation of the immune recognition of such emerging cell clones would
be designed to delete such cells. The intracellular surveillance system (p53-mediated) for unscheduled
DNA replication is also a necessary target for inhibition [35], as is the nature of the cell telomeres,
whose erosion leads to senescent deletion of cells with critically shortened telomeres [36].
The cancer stem cell (CSC) hypothesis states that not all of the cells in the tumor are able to
reconstitute the tumor mass after dissociation and that a sub-population of cells are responsible for
tumor initiation, and post-treatment relapse. The CSCs have been termed stem-like cells, since their
properties, and some phenotypic characteristics replicate the tissue-renewing stem cells in normal cell
systems. It is assumed that the pool of CSCs, which is between 0.01% and 0.1% of a prostate cancer
mass lies at the apex of an aberrant differentiation hierarchy (see Figure 1).
The more traditional view of carcinogenesis is embodied in the stochastic mechanism which
proposes that the definitive carcinogenic event is initiated by an oncogene or tumor suppressor gene.
The mutation is “fixed” in the population by subsequent mitosis, resulting in a daughter cell whose
tumor propagation potential matches that of the initiating cell. Subsequent mutations and accumulation
of different genetic lesions within the initiated “field” produced clones with growth advantages that
can be traced to the founder event. There is now increasing evidence in prostate cancer (reviewed in
Reference [37]) to show that epigenetic inactivation (CpG methylation ratios) of APC and RARβ genes
in malignant tissues and adjacent histologically normal cells, imply the existence of an “epigenetically
activated field” of cells [38], as seen in oral squamous cell carcinomas [39].
It is likely that the CSC and stochastic hypotheses are not mutually exclusive. Experimental
evidence requires the initiating events to occur in longer lived and largely quiescent stem/progenitor
cells, establishing pre-tumor development [34] which may be histologically undetectable, and provide
a longer-term pool of “reserve cells”. However, in later-stage or aggressive disease a CSC-derived
dominant clone, which shares founder mutations with the original clone but has enhanced proliferative
and invasive capabilities could drive the cancer. Genetic heterogeneity and phenotypic plasticity can
also be maintained in the original CSC pool to allow new and evolutionarily successful clones to
develop in response to changes in microenvironment, such as treatments [40].
3. Gene Expression Changes During Epithelial Differentiation in Normal and Malignant Prostate
Since our original hypothesis was that in both normal and malignant prostate, the bulk of the
cells is derived from an original (basal) stem cell [29], it is important to understand the controls
which affect stem cell differentiation within the basal compartment. Whilst many markers have been
devised to distinguish between the basal and luminal compartments (mostly upregulated genes in the
luminal compartment), relatively little is known about gene sets and their changes in expression as
a basal cell matures from an initial stem cell. To approach this, we exploited a gene expression data
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set [41], which defined gene expression within the putative stem cell population (CD133+/α2β1integrin
high/CD44+) and the more differentiated basal cells loosely grouped into a committed basal cell type
(defined as CD133-/α2β1 integrin low/CD44 high) (Figure 1A). We adopted this approach to minimize
overlap within the continuum of change which is normally seen between stem cells and those basal
cells committed to differentiation as shown in the figure, and to overcome the limitations of cell surface
phenotype base enrichment where a “pure” stem cell population is likely to contain about 5% TA
cells [42]. Luminal cells are also likely to contaminate the basal cell population, although by adopting a
short-term adhesion and growth in culture strategy, luminal cells do not normally survive [43].
Our second assumption was that genes whose expression is changing during the differentiation
process ought to be co-regulated in some way. Therefore, we re-analyzed our initial gene expression
data on the basis of a high pair-wise correlation (Figure 2A) i.e., genes whose expression always
moved up or down with at least one other gene in the group. We were able to identify four interaction
networks of genes, which clustered closely together, Group A, B, C and D genes [26] (Figure 1A, Table 1).
There were two additional striking features of this analysis. The first was that the four groups of
interactomes were quite distinct, with no interconnections as often found in similar studies. Secondly,
all four groups corresponded quite closely to particular elements within The Gene Ontology with the
exception of Group A—the least tightly associated gene cluster [26]. Group B genes were associated
with cell cycle and chromatin condensation, Group C, epidermal differentiation and endopeptidase
activity, while Group D contained genes previously associated with cellular development. To extend the
correlation, we analyzed a compendium set of 24,536 human Affymetrix gene expression microarrays
from 800 experiments available online, containing expression data from at least 150 different human
cell types, i.e., extending the gene co-expression to beyond just prostate epithelial differentiation.
The final dataset contained about 1.2 billion expression correlations and clearly indicated that our
initial grouping of co-regulated genes, based solely on prostate epithelial differentiation, was retained
across many human tissues, implying that the control factors for such genes are highly conserved
within different human pathologies and human differentiated cell types. Multiple transcription factors
and a variety of steroid hormones were readily identified as potential primary regulators of the
differentiation-associated gene sets in the prostate, for example, the tightly clustered Group C genes
(associated with epidermal differentiation) [44,45]. Androgens, which control the terminal elements of
prostate differentiation [46] had no discernable effect within the basal compartment whereas they were
the primary driving force behind gene expression in purely luminal cells such as the LNCaP cancer
cell line. The high biological activity of RA is perhaps not surprising, given its well-known effects
on (i) cellular differentiation [44,47] (ii) cancer treatment (reviewed in [48]), and (iii) its potency in
re-aggregation cultures of prostate cancers [49]. It was concluded that both retinoids and androgens
are required to promote functional differentiation and that there should be a number of genes which
are dually regulated by retinoic acid and androgens as the prostate differentiation pathway process
proceeds [50]. Within the promoters of these genes e.g., the prostate transglutaminase (TGM4), the AR
binding sites are in sufficiently close apposition to the pre-occupied retinoic acid binding site to imply
that as androgen receptor levels in the nucleus increase, the bound retinoic acid response complexes
are deposed by the AR complexes, resulting in a proposed switch for retinoic acid control to androgen
receptor control [50].
However, such simplistic mechanisms cannot explain all of the co-regulations seen within the four
expression groups during basal cell differentiation. An equally powerful regulator of co-expression
would also seem to be high levels of a restricted number of transcription factors (Table 2) which could
act either in combination or individually to regulate different genes. For example, ROCK2 has also been
previously implicated in prostate cancer differentiation [51], and indeed inhibitors of Rock are used in
specialist media to preserve a stem cell-like phenotype [52]. The range of these “master” transcription
factors which are overexpressed during the differentiation process is listed in Table 2.
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In terms of gene expression responses and co-regulation, the TMPRSS2 gene (frequently regarded
an androgen “specific” gene, found in an active fusion with the ERG oncogene in about 50% of prostate
cancers) [53] was clearly upregulated by androgens (12 fold), as expected, in the luminal compartment,
but showed an even higher upregulation (40 fold) within the basal compartment from a base state
under the influence of retinoic acid [26,54]. This is entirely logical, given the transcription profile
of TMPRSS2, which clusters with HTGP4 and since TMPRSS2 is expressed at detectable levels in
other non-prostate tissues, which do not express AR [50], according to the Human Protein Atlas:
https://www.proteinatlas.org/ENSG00000184012-TMPRSS2.
Identification of the cognate binding sites within promoters for transcription factors and the range
of differentiation-associated transcription factors (Table 2), has posed the question: What is controlling
the expression of the differentiation regulatory transcription factors? Based on epigenetic controls
known to act on such differentiation cascades in embryonic tissues, these are unlikely to be mutagenic
effects or indeed mediated by genome re-arrangement, since they occur both in normal prostate and in
the malignant equivalent. The control requires flexibility, reversibility and immediacy of action in cells
to changes in micro-environment, ultimately resulting in prostate epithelial cell differentiation.
4. Epigenetics: A Mechanism for Phenotypic Flexibility in Development and Disease
Most current therapies for prostate cancer are directed against replicating differentiated cells [55],
but the unique properties of a stem-like population render the latter undifferentiated cells resistant
to virtually all treatments (see below). However the ability to differentiate appears to be hard-wired
into all such stem-like cells, therefore one solution would be to deplete or eliminate the stem cells
by inducing differentiation which is aberrant in prostate cancers [48]. This strategy works clinically
in leukemia, where pre-treatment with retinoic acid results in a more differentiated cell, which can
then be killed by traditional chemotherapies [56]. Similarly, the use of epigenetic manipulators of
undifferentiated state such as histone deacetylase inhibitors [57] has been exploited to deplete the
stem-like population in experimental breast cancer [58].
5. Defining Epigenetics in Human Genetics: The Elegance and Simplicity of
Waddington’s Concept
In a purely theoretical analysis of cell fate determination in development, Conrad Waddington [59]
visualized his “epigenetic landscape” as an inclined surface with lower branching ridges and valleys
(Figure 1B). Waddington’s model provided a connection between genotype and phenotype, which in his
opinion was not rooted in mutation (during development) but rather defined epigenetics as “Heritable
changes in gene expression (active vs inactive genes) which does not involve changes to the underlying
DNA base sequence i.e., a change in phenotype without a change in genotype’. The reversibility of the
differentiation continuum or rather its effects on phenotypic plasticity has been elegantly demonstrated
in induced pluripotent stem cells [60] which requires “energy” or multiple gene mutations/activations
to promote a cell “upwards” to the SC state.
Waddington formulated these hypotheses in the complete absence of any potential epigenetic
mechanisms in development or indeed cancer [61]. We now possess an appreciation of the diversity
of such control via three mechanisms (i) DNA methylation, principally, but not exclusively at CpG
sites, often in clusters within the human genome (ii) the status of chromatin (condensed, relaxed)
which is determined by the modification status of the histones (acetylation, methylation) bound at
specific sites and (iii) the expression of non-coding RNA such as microRNAs (miRNA) which can
control the expression of multiple genes by recognition of target sites in mature mRNA, resulting in
their destruction by potent and specific ribonuclease complexes. The relevance of epigenetic control in
cancer development has recently been reviewed [62] and epigenetic changes, in the absence of common
mutations, seem to underpin the development of malignant pancreatic cancers [63].
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6. Epigenetics as a Flexible Response to Environmental and Microenvironmental Changes
In evolutionary terms, a permanent change such as mutation or deletion of a gene is clearly a
strategy for many species. In cancer, however, a permanent response to drug treatments such as
AR gene amplification/mutation [64] or DHFR amplification in response to methotrexate [65] cannot
be undone when the treatment is withdrawn, or a compensation pathway is activated in the cancer
cells. Normal and cancer stem cells are designed to survive multiple environmental challenges over a
lifetime, and epigenetics provides rapid and flexible responses that are required [66].
7. The Epigenetic Landscape in Prostate Cancer
Returning to Waddington’s original Landscape, on to which the various epithelial cell types in
normal and malignant prostate have been superimposed (Figure 1B), it is clear that substantial “energy”
is required to promote a fully differentiated luminal cell into a stem-like cell [61]. Current attempts to
achieve this by iPSC techniques have not been successful [67], and in the laboratory, whilst there is some
plasticity between TA and SC, and a lower degree from CB and SC, luminal cells generated in vitro
appear programmed to secrete “prostate-specific” products and senesce (Figure 1A) [68]. However,
whilst this holds true for normal epithelial hierarchies, there may be a higher degree of plasticity
in a tumor cell: where nevertheless biological energy must be spent to achieve the transition to a
stem-like status.
8. Small Non-Coding RNAs: The Rapid Reaction Force for Environmental Changes in
Differentiation and Cancer Treatment Suppressor miRNAs and Onco-miRNAs: Designed or
Selected for Cancers?
Small non-coding RNAs, such as the more than 2000 microRNAs (miRNA) encoded in the human
genome are a major mediator of epigenetic gene expression control [69]. Bearing in mind the earlier
data indicating that cell fate decisions in prostate basal cell differentiation requires simultaneous control
of a number of genes, and in particular a defined suite of transcription factors, specific miRNAs are
good candidates to provide this level of simultaneous gene regulation. Specific miRNAs affect cell
fate (and gene expression) in both human embryonic stem cells and induced pluripotent stem cells
(reviewed by Reference [70]), and miRNA levels are generally higher in the least differentiated (stem
cell) populations.
Increased miRNA expression has also been linked to oncogenic changes—suppressing tumor
suppressor genes there (onco-miRNAs) whereas some are downregulated, permitting the expression
of known oncogenes (suppressor miRNAs). Unlike many other studies in common tumor types,
there has been little consensus about the most significant miRNA expression changes in prostate cancer
(reviewed by Reference [71]), whilst individual miRNAs have been associated with poor outcomes in
prostate cancer patients [27] and cell lines [72,73].
When miRNA levels were studied in purified cell fractions from multiple normal and malignant
prostate tissues (Figure 2B), there was no relationship between miRNA expression patterns and
pathology, whereas unsupervised clustering indicated a close relationship to epithelial differentiation
(the most significantly altered miRNA species are shown in Table 3). As frequently reported in ESCs,
the prostate stem cells (of both malignant and non-malignant origins) expressed the highest levels
of miRNA, which decreased as the cells differentiated and more gene sets were transcribed in the
differentiated luminal cells [28].
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Table 3. Principal miRNA classes implicated in prostate epithelial cell differentiation.
SC Signature Specific PCaCSC Signature
Specific CRPC
CSC Signature
Upregulated miRNA
miR-302 family miR-33a * let-7i *
miR-371 family miR-181a-2 * miR-136
miR-484 miR-323-3p miR-143
miR-548c-3p miR-411 * miR-214 *
miR-487b miR-362-5p
miR-532-3p miR-516a-5p
miR-1271 miR-542-5p
miR-545
miR-1913
Downregulated miRNA
let-7 family miR-302c miR-125b-2 *
miR-8 family miR-519c-3p miR-708
miR-10 family miR-574-5p
miR-17-92 family miR-1181
miR-99a/100
miR-143
miR-145
Upregulated miRNA indicated in green; Downregulated miRNA in red. CRPC = castration-resistant prostate cancer;
CSC = cancer stem-like cell; PCa = prostate cancer; SC = stem cell. * Lower prevalence product of a specific miRNA
locus. Data taken from References [27,28].
9. Developmental Changes in miRNAs in Prostate Epithelial Cells of Normal and
Malignant Origins
The miRNA expression profiles showed that (i) a miRNA signature was conserved in stem cells
from BPH, PCa, and CRPC, implying that miRNAs play their most important role in regulation of
essential SC properties such as self-renewal, prolonged proliferation, and a hard-wired capacity to
differentiate, regardless of the pathological origins of the cells. (ii) The prostate SC miRNA signature
overlapped considerably with that from human embryonic SCs (hESCs) [74] e.g., high expression
of the miR-302 and miR372 families but suppression of the let-7 family (Table 3). (iii) The miRNA
expression profiles of SCs and those of previously published unfractionated CRPCs [75] overlapped by
approximately 60%. The shared suppressed miRNAs have previously been shown to regulate key
SC and cancer-associated proteins such as c-MYC, KLF4, NANOG, and EZH2 in SCs and CRPCs.
(iv) The PCa-cancer stem-like cell (CSC), CRPC-CSC, and normal SC populations each had significantly
different miRNA expression signatures, which distinguished them from their more differentiated
cell progenies.
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Given the strong link between differentiated state and miRNA expression in this study, a number
of the previously prostate cancer (both primary and CRPC) -associated miRNA identified in Rane et
al., [27] had previously been reported to be onco-miRs and tumor suppressor miRNAs, such as (i)
miR-629 and miR-203 [76,77] (ii) suppression of miR-299-5p, which is down-regulated [78] in metastatic
cell lines compared with normal prostate epithelial cells, and (iii) the CSC signature identified miR708
whose suppression in prostate xenograft cells unregulated both CD44 and Akt [79], whereas the CRPC
signature implied that miR-521 was implicated in a radio-resistant LNCaP phenotype) [80].
Finally, since multiple miRNAs implicated in the hESC maintenance program are conserved
in adult human prostate epithelial SCs, this strengthens the evidence for a stem-like status for
CD133+/CD44+/a2b1 integrin high cells—a status which is ultimately acquired by malignant cells in
CRPC after multiple rounds of androgen-based therapies, emphasizing the basal stem-like nature of
these advanced. and broadly incurable cancers [81].
Bioinformatic analysis to identify the most significant changes in expression has recently been
compromised in unfractionated tumor biopsies in a paper describing the expression of the onco-miRNAs
143/145 in normal mouse colon [82]. Previously considered to be markets of malignant epithelium,
a cell-specific study found that the major 143/145 expressing cell type was a stromal cell, although this
did not seem to be the case in prostate epithelial cells [27,83]. Changes in miRNA expression using
RNA from heterogeneous cancer biopsies were, therefore, a result of changes in the stromal content of
the biopsies.
We sought to minimize the impact of our study of epithelial differentiation, by restricting
the candidate genes suppressed by miRNA control after referral to a range of existing algorithms
(MiRWALK) to those which were actually expressed in prostate epithelium [28]. Secondly, rather
than focus on individual genes, we correlated the changes in miRNA expression and their target
genes to cellular functions, exploiting the Gene Ontology Database. Again, we used co-expression
patterns to cluster the miRNAs, and identified seven groups, which were related in their mRNA targets,
and the seed sequence similarities [84]. Since miRNAs of known similar functions (e.g., let-7 and
miR-17-92 families) did cluster together, we identified significant functions with increased confidence.
Both Notch signaling and DNA damage repair emerged as the outstanding significant functional
candidates (Figure 2C) for epigenetic control by miRNA during prostate epithelial differentiation [28].
10. Phenotypic Plasticity and a Stem-Like State as a Mechanism for Radio-Resistance
It has been suggested in studies of other cancer types, that both the induction of a more stem-like
state and chromatin status play a dual role in radio-resistance [85–90], as we have shown in primary
cultures of prostate epithelium (see below). The separate and unbiased discovery of DNA damage
repair as a major miRNA-controlled function in prostate differentiation [28] prompted a search for
potential candidate genes whose expression might be specifically regulated.
Phenotypic plasticity, and the generation of cells with a stem-like phenotype from more
differentiated cells, has also been implicated in therapy resistance. Since our miRNA dataset implied
such a close relationship between treatment-resistant cells (CRPC) and that miRNA could perturb
differentiated state. Here, our candidate selection was driven by the set of transcription factors
identified earlier: i.e., RXR, Rock2, vitamin D receptor, GCRs, TAZ serum response factor and HSF1.
Within the set of miRNA over-expressed in SC, one miRNA: miR548c-3p had a high potential to
control the differentiation-linked transcription factor expression set. This miRNA is overexpressed
approximately fivefold in SCs compared with more differentiated cells, and its overexpression has been
associated with poor patient survival [76]. When miR548c-3p was overexpressed in CB cells (i) a more
stem-like phenotype (CD49b (integrin b2) and CD49f (integrin b6)) was generated (ii) colony-forming
efficiency (an indicator for SC self-renewal capacity) increased by 75% (iii) mRNA expression of
multiple SC-regulated genes (e.g., up-regulation of NFKB ID2 PROM1 and SOX2) with a simultaneous
reduction in CB cell-specific genes (CEACAM6, WNT5A, LCN2), but perhaps most significantly (iv)
the radiosensitive CB cells became more resistant to 5Gy of x- irradiation [27]. Over-expression of
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miR-548c-3p has previously been shown to reduce doxorubicin-induced DNA damage in HeLa cells
by inhibition of DNA topoisomerase IIa [91]. This is a clinically relevant result since in untreated
tissue-derived CRPC cells, miR-548c-3p was significantly unregulated compared to benign cell-derived
epithelial cells and higher serum levels of miR548c-3p were found in CRPC patients compared to
serum from low-risk PCa patients [92].
11. Increased Heterochromatin and Rapid Chromatin Condensation as a Mechanism for
Radio-Resistance in Prostate Cancer Stem Cells—The Role of Histone Modifications
Stem cells contain bivalent or “poised” chromatin, which share active and repressive histone
binding [93,94]. The distribution of such marks changes radically as the stem cells differentiate and
differentiation-specific genes are activated. In embryonic stem cells, which have a high degree of
pluripotency, the existence of bivalent chromatin marks permits rapid activation or repression of genes
required during the first essential step in differentiation i.e., self-renewal [95,96].
The existence of condensed or bivalent chromatin has been proposed as a response and resistance
mechanism to a number of therapies for cancer [97–99]. Primary epithelial cultures of stem-like
cells derived from patient prostate tissue (CD133+/α2β1integrinhi) sustained less DNA damage
and were, therefore, more resistant to radiation than the more differentiated transit amplifying
(TA) and committed basal (CB) cells [100]. In retinal rod cells [101], preferential localization of
radiation-induced DNA damage foci was seen in euchromatin whereas the nuclei of untreated stem
cells in primary prostate epithelial cell cultures presented with higher levels of heterochromatin (and
less euchromatin) than the TA and CB cells, as shown by staining for histone marks H3K9me3 and
H3K27me3, using immunofluorescence and flow cytometry. Following low dose irradiation (2Gy),
the heterochromatin rapidly adopted a distinctive and highly condensed conformation, which was not
observed in the more radiation-sensitive TA and CB cells. There was a lower overall percentage of
cells positive for DNA damage foci post-irradiation, but the cells that did stain for DNA damage foci
showed no overlap of heterochromatin and foci; i.e., any foci were located in areas of euchromatin
(Figure 3). We reasoned that chromatin de-condensation should increase DNA damage and therefore
the effectiveness of radiotherapy for the stem cell fraction. Pre-treatment of the SC population with a
low (non-cytotoxic) dose of Trichostatin A (TSA), a histone deacetylase (HDAC) inhibitor, increased
the radio-sensitivity of the SC fraction by 20%–40%, whilst not affecting the more differentiated and
radio-sensitive cells. A significant synergy with radiation after treatment with another (clinically
approved) HDAC inhibitor, Vorinostat (suberanilohydroxamic acid—SAHA) was observed in multiple
primary prostate epithelial cultures [102] as defined by colony forming ability.
Like many other stresses, hypoxia [103] also results in alterations to transcriptional regulation
resulting from epigenetic changes including chromatin remodeling [104]. Hypoxic conditions have
been shown to induce chromatin compaction in some cells, those undergoing arrest and apoptosis, and
induction of bivalent chromatin [105]. If this occurs within the tumor, it could also contribute to the
radio-resistance mechanisms within the hypoxic region. Overall, the current data for prostate cancer
strongly promotes the use of the HDAC inhibitors (at sub-cytotoxic doses) as radiosensitizers in a
combination treatment in much the same way as exploited in clinical trials for other cancer types [106].
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Figure 3. Nuclear architecture and foci of DNA repair in prostate epithelial cell subtypes. Primary
prostate epithelial cells were cultured and separated into stem cells (SCs), transit amplifying cells (TAs)
and committed basal cells (CBs). Each cell population was irradiated with 2Gy irradiation and cells were
fixed and stained 30 min post-irradiation for nuclear stain (DAPI) (blue) heterochromatin (H3k9me3)
and γH2AX (green). Unlike TA and CB cells, where the majority of cells (~80%–95%) showed DNA
damage (γH2AX foci) post-irradiation, only ~40% of SC were positive for foci. This trend was observed
in 13 BPH (benign prostatic hyperplasia) samples and 15 prostate cancer samples. The SCs that were
negative for foci had a distinctive heterochromatin pattern. In the SCs that were positive for foci,
the foci did not coincide with the regions of heterochromatin. Images represent (A) unirradiated stem
cells with no foci, (B) irradiated stem cells with no foci (60% of cells) and (C) irradiated stem cells with
foci (40% of cells). Three examples of each group are shown (i), (ii) and (iii) [100].
12. miRNA-Induced Changes in Chromatin Status as a Mechanism for Radio-Resistance in
Prostate Cancer
Many miRNAs play a variety of roles in resistance to chemotherapy, and the Gene Ontology
link from our linked profiling of mRNA/miRNA implied that the same feature would apply to
radiotherapy-induced DNA damage repair [27,28]. miR-99a/miR-100 was one candidate family
downregulated not only in SC and CSC but also in patients with CRPC (compared to benign disease).
Furthermore, patients with low levels of miR-99a/miR-100 are more susceptible to biochemical
recurrence after treatment [76].
When expression was studied in both cell lines and primary tissue-derived cells, inhibition of
miR-99a/miR-100 prevented p53 dependent apoptosis in irradiated PCa cells. In a similar manner to
HDAC inhibitor treatment (see above), suppression of miR-99a/100 results in relaxation of damaged
chromatin by both histone acetylation and recruitment of DNRCA1 and RAD51 [107]. Of the
mRNA targets of miRNA99a/100, SMARCA5 and SMARD1 were identified at the principal drivers of
resistance [107,108]. No effects were seen on stem cell phenotype, despite previous studies showing
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that the related SMARCA3 cooperated with the relevant transcription factor EZH2 in epithelial stem
cell maintenance [109].
Expression of PARP1 whose inhibition was recently shown to increase survival times a subset
of PCa patients [110], is another essential component of the miR-99a/100 driven DNA damage
response [111]. When PARP inhibition was tested as a potential enhancer of radiotherapy in PCa using
either siRNA against PARP1 or nicotinamide (a non-selective PARP inhibitor), recruitment of both
SMARCA5 and, to a lesser extent, SMARCD1 was inhibited [108]. Thus, the established PARP activity
forms a radiation resistance network with the miR-99a/100-SMARCA5/SMARCD1 axis. The more
commonly observed induction of epithelial-mesenchymal transition [112] as a resistance to PARP
inhibition or miR99a/100 manipulation was not observed in our studies [108]. We also showed that
expression of miR99a/100, like miR708 in ovarian cancers [113] was susceptible to control by hormones,
most notably glucocorticoids, by an as yet undetermined but probably indirect transcriptional control
mechanism. This raises a serious clinical question about radiotherapy (and chemotherapy) treatment
protocols, where patients are often administered glucocorticoids to counteract the side effects of
radiation. Clinical studies have demonstrated that GCR inhibition promoted docetaxel resistance
in PCa [114], and GCR is expressed at significant levels in the chemo- and radiotherapy resistant
CSCs [41], after pre-treatment with Dexamethasone or the GCR inhibitor. In our experiments on
near patient samples, the GCR inhibitor mifepristone produced sensitivity changes of primary PCa to
irradiation, by directly influencing the expression levels of miR-99a/100 [108]. Therefore, the use of
GCR inhibitors rather than glucocorticoid supplements should clinically enhance radiotherapy and
perhaps reduce tumor relapses.
13. The Paradoxical Role of Genomic Methylation in Prostate Epithelial Differentiation
and Carcinogenesis
Control of cell fate really cannot be explained by any single transcription factor (see Table 2).
Whilst activation of gene expression by suppression of miRNAs (see above) has the potential to
affect many genes simultaneously, it is likely that binding of modified histones to transcriptional
control mechanisms provide a form of reversible primary control in gene regulation, for example as
demonstrated in radiation resistance.
Persistent changes to DNA are stabilized by CpG hypermethylation in many cancer types
(reviewed by Reference [62]) including primary prostate cancers [115], although demethylase activity
offers a degree of flexibility [97]. In embryonic and other stem cells, hypomethylation with foci of
hypermethylation is generally observed [116,117] presumably to block the expression of stem cell
suppressors. As differentiation progresses, higher and more general patterns of methylation emerge,
particularly as a differentiated cell becomes more specialized in secretion patterns, like luminal cells
in a normal prostate, and as described earlier for miRNA expression, which also functions as an
expression repressor.
The ability of CpG methylations to control the expression of many genes in cancer has been
extensively reviewed [62]. Glutathione S transferase (GSTP1) is an outstanding example of such
methylation-driven control in the prostate [118,119], and genome-wide studies have been able to
distinguish the methylation phenotypes of normal and malignant tissues and cells [120]. However,
as the resolution of the analyses has improved, so have the subtleties associated with genomic hypo- and
hyper-methylation. Firstly, methylation patterns in extracts of cancer biopsies are notoriously variable,
certainly compared to cell cultures [121]. Tissue cell heterogeneity is a major influence on this, and has
stimulated studies of cell-type-specific methylation in cells fractionated from tumors [122,123] in which
many of the cancer-associated methylation patterns were reassigned to control of differentiation (i.e.,
a predominance of prostate luminal cells and loss of basal cells in cancer) and the replicative state of
the previously terminally differentiated luminal cells. However, this was not an absolute rule, since
oncogene activation has been reported through the loss of promoter DNA methylation [124]. Promoter
hypomethylation in prostate cancer has also been reported to facilitate aberrant expression of Wnt5a
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affecting tumor malignancy [125], and the up-regulation of Wnt signaling by circulating tumor cells
(CTCs) in CRPC patients [126].
Gene expression studies, closely coupled to genome-wide CpG methylations in prostate tissues
have found that there was a relatively low correlation between the two phenomena, unlike similar
studies in established cell lines [127]. In fractionated cell populations from prostate cancer tissues,
we have recently identified sets of genes which displayed epigenetic control mediated by CpG
methylations, but the strongest link remained with differentiated cell status: hence the apparent
hypermethylation seen in cancers, with its predominantly (although aberrant) luminal phenotype [123].
As a test of this hypothesis, we have recently carried out a genome-wide DNA sequencing of
bisulfite-modified DNA extracted from multiple cell types, enriched according to their phenotype [128].
In contrast to all previous studies, the cells used had been directly enriched from disaggregated
tissue biopsies of radical prostatectomies. In addition to a scan-directed intra-tumoral biopsy, we also
obtained a normal tissue biopsy from a cancer-free location in the patient’s gland. The presence/absence
of cancer in the tumor/normal needle cores was confirmed by subsequent histology. The procedure
is outlined in Figure 4. After the methylated CpG sequences had been assigned to various loci,
the closest association between patterns of methylation assigned different samples to the original
patient, followed by the differentiated cell type of origin. Therefore, many of the existing genome-wide
CpG methylation signatures for prostate cancer [120,129] will be contaminated with patient-specific
signals and affected by the cellular composition of the biopsies used. To overcome this bias, the patient
and cell-type specific signals were removed, allowing a direct comparison of non-malignant vs
malignant epithelial populations in each patient. Here, very few CpG methylation changes were
seen in the basal compartment: all of which were related to the gene ontology terms cell motility and
cell adhesion—both essential properties of a cancer stem-like cell relative to its normal equivalent.
However, for a comparison of normal and malignant tissues to be valid, and perhaps applicable in
the clinic, normal luminal cells relative to the 99% of luminal-like cells in cancer biopsies are the most
useful comparison. When this was carried out, again relatively few gene ontology terms were involved,
but most notably CpG methylation was related to the luminal cell proliferation in cancer, relative to
the terminally differentiated non-dividing status of normal luminal cells.
Since these signatures had the cell and patient-specific elements removed, they were then applied
to existing CpG methylation data in the TCGA prostate cancer database [115]. Unfortunately, the TCGA
data were obtained from methylation oligonucleotide arrays, so the sequencing data was compressed
into 100bp “bins” to match the two resources. This results in a loss of resolution. From TCGA
data, the 553 patient analyses (of which 50 also had patient-matched normal tissues) contained 255
methylation array loci overlapping 1472 differentially methylated sequences. We were able to identify
a small number of DMRs (differentially methylated regions) (8 × 100 bp sequences) which could
distinguish normal from cancer luminal epithelium at a 96% efficiency. In fact, because the data
eliminated patient and other cell type signatures, this assay should be able to find even small areas of
cancer within normal tissues at the same efficiency.
Secondly, since the original tissues used to establish the signatures were from high Gleason grade
samples, we next asked whether this signature was able to distinguish tumors with a poor outcome
from those which remained organ-confined. Again, all of the relevant clinical outcomes were included
in the TCGA information. By using 60% of the database information as a training set, we were able
to devise a 17 DMR signature for patients whose cancers were likely to have spread. This resulted
in a 76% detection rate for poorer outcomes, but from an original radical prostatectomy sample,
i.e., at an earlier time before conventional technology such as MRI scanning could be used to locate
micro-metastases. Thus, malignancy seems to be fixed in the CpG methylation patterns from an early
time in cancer development. With more patients and matching of methylated CpG technologies (i.e.,
direct sequencing) this analysis could offer an early diagnosis of the most malignant prostate cancers.
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Figure 4. Fractionation strategy for genomic methylation analysis of discrete cell subpopulations from
the prostate. Fractionation from total tissue biopsies as described in the text eliminates the influence of
dominant cell populations and also eliminates artefacts of in vitro cell culture [128].
The analysis also had a sounder mechanistic basis than an empirical serum PSA level increase.
The cancer-related hypermethylated regions detected in the luminal compartments were normally in
upstream enhancer regions, outside of CpG islands, Shores and Shelves [130]. As determined
by reference to the ENCODE data, conserved enhancers more than 5 kb from transcriptional
start sites [81] showed the most divergent CpG methylations. The DMRs were also marked
by evolutionary conservation [131] the presence of “open” chromatin (detectable by DNAase I
hypersensitivity) [132] and known transcription factor binding sites, previously found by genome-wide
chromatin immunoprecipitation [133]. Expression of components of the polycomb complex such as
EZH2 and SUZ12, previously shown to be overexpressed in prostate cancer [134,135], was controlled
by CpG methylation, as were the transcription factor binding (TFB) sites in the upstream regions of
TP63, TP53 and NF1. Hypomethylation was present in FOXA1, NFKB and GATA3 TFB sites in addition
to a number of repetitive sequences collectively known as LINE and LTR but not SINE sequences,
so hypomethylation was not simply a feature of nucleotide base repetition. Whilst established CpG
methylation-controlled genes did show specific hypermethylation e.g., upstream of GSTP1 and CCDC8,
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in this case, it was apparent in the basal: luminal cell comparison and was located in the more
widely studied promoter regions (CpG islands)—differentiation linked rather than associated with
pathology [128].
14. Epigenetic Control of Random Mono-Allelic Gene Expression in Development and Cancer
Epigenetic control of gene expression is normally considered at the single gene level (e.g.,
CpG island methylation and GSTP1). However, most mammalian cells are diploid and prostate cancer
cells are normally either quasi-diploid (hormone naïve) or aneuploid (CRPC), containing at least two
copies of all non-sex chromosomes. One notable exclusion is the X-encoded androgen receptor with
its critical role in PCa, although amplification of X and AR genes is seen in CRPC [64]. The selective
silencing of one X chromosome in female cells [136] and persistence of gene expression from the
maternal X chromosome in non-embryonic tissues during development [137] were prototypes for
similar mono-allelic expression studies in the human autosomes.
High-resolution genome sequencing has now provided unprecedented details about the allelic
nature of oncogene activation in prostate cancers, where most mutagenic changes are heterozygous,
retaining a copy of the normal allele [115]. According to classical theory, all such oncogenic mutations
should act in a dominant manner, and the activated gene product should be expressed in the cancer
cells. However, selection of allelic preferences in multiple genes during mammalian development is
controlled in a random fashion, unless it confers a selective advantage on a cell in which it expressed,
overcoming the biological defenses against cancer development [138].
The presence of the normal allele is rarely considered when determining new potential therapeutic
targeting and indeed understanding the cancer. As normal cells and tissues develop from a stem cell
origin, virtually every cell inactivates one chromosomal copy by epigenetic mechanisms. Patches of
clonally derived cells are also present in most tissues, for example, multiple cell patches containing
inherited mitochondrial DNA mutations in the normal prostate [139].
An elegant single cell transcript analysis of allelic expression in developing mouse embryos
showed mono-allelic expression of 12% to 24% of autosomal genes [140]. A generally stochastic pattern
of monoallelic expression was seen, which differed from that in cells displaying allelic exclusion and
genomic imprinting, whilst considerable variability was seen amongst closely related embryonic
cells, and the phenomenon was also observed in more differentiated cells from mouse tissues [141].
Here, individual cells demonstrated a form of transcriptional bursting [142] independent surges of
transcription could occur from both alleles over time in the same cell, but only RNA from a single
allele was present at any given time.
15. Random Monoallelic Gene Expression in Human Cancers
Different cancer cells are likely to display variant allelic preferences between genes. Such Random
Monoallelic Expression (RME) is distinct from expression controls established by aberrant promoter
methylation, or locus deletion detected in cancers. In RME, the alleles of a specific gene can be (i)
biallelically, (ii) maternal monoallelically, (iii) paternal monoallellically expressed or (iv) completely
silenced. The expressed allele is stably retained after mitosis and differentiation in non-stem daughter
cells [54,143]. From this point monoallelic expressing cells populate the tissue, creating an expression
mosaic pattern based on initial allelic activation in the founding CSC. This mosaic expression pattern
has been found in glioblastoma driver genes [144]. Whilst RME is most readily observed in tumor cell
cultures [145], the contention that the phenomenon was an in vitro artefact has now been dismissed by
in vivo analyses. [143,146].
In the majority of genes displaying RME, regulation of allelic choice is, however, not controlled
by strand-specific methylation [54,144] of promoter CpG islands [147] as originally proposed [148].
High-resolution promoter analysis implies that RME is defined by an asymmetric chromatin signature
in which histones within the gene body of an active allele are tri-methylated at H3K36 and the silenced
allele methylated at H3K27 [146]. Regulation of allele-specific expression is therefore hardwired into
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chromatin, and many of the genes discovered in these screens were also present in bivalent chromatin
loci, which is defined by dual deposition of activating (H3K4me3) and repressive (H3K27me3) histone
“marks” at promoter regions, which is assumed to permit rapid activation of genes upon stem cell
differentiation [149], as we have shown for prostate cancer stem-like cells [54]. Another pertinent
example of allelic suppression is the haplo-insufficient expression of the PTEN gene in prostate
cancers [150–152]. Whilst mutation/loss of both PTEN loci on chromosome 10 is common in CRPC,
primary prostate cancers retain a normal allele, and PTEN is expressed in tissue extracts in low
amounts [115,153]. RME would predict that complete silencing is seen in a proportion of cells, whereas
in others the normal allele can be expressed at cytoprotective levels since homozygous knockouts
result in high cancer rates but are also embryonic lethal [154].
Tumorigenic RME has been reported in peripheral mononuclear blood cells from chronic
lymphocytic leukemia patients with DAPK1 haploinsufficiency [155], whereas in hepatocellular
carcinomas, Illumina SNP chips identified 17 monoallelically expressed genes, 58 allelic genes with
allelic imbalance, and seven genes showing allele substitution [156]. This silencing of activated
oncogenes by RME has been reported in other common cancers, including colon and breast [157,158],
but its effects are best illustrated in multiple myeloma, where only 27% of mutated genes (11%–47%)
found in the cancer cells are actually expressed [159] in heterozygous cells, where the normal allele is
preferentially transcribed.
The expression of TMPRSS2—which provides the promoter for the TMPRSS2-ERG fusion, presents
in about 50% of organ-confined prostate cancers, the commonest genetic abnormality in prostate
cancer, [10,53] is strongly regulated by RME. This perturbation of RME in prostate cancer is again the
result of epigenetic control by histone code rather than by CpG methylation, generating epigenetic
plasticity in the propagating cell, and resulting in expression heterogeneity [54].
Within a mass of identical cancer cells, epigenetic control of RME can both silence tumor suppressor
loci and activate oncogenic alleles. However, it is now clear that tumors are not a homogeneous
mass of identical cells. Pre-tumor progression, where mutations accumulate in a phenotypically
silent manner has been proposed as the source of the multiple cooperating driver mutations in the
final tumor. It is perhaps significant that treatment-naive prostate cancers have relatively few p53
mutations [160], to render the cells less susceptible to the “genomic protection” function of p53 and
apoptotic death when a mutation is detected. However, this does not preclude epigenetic p53 silencing
to permit cell replication and establishment of mutagenic changes. The same can be argued for
changes to the immune suppression pathways, which normally result in the destruction of a cell
expressing a neo-antigen. Allelic suppression as seen in RME would also suppress any endogenous
immunosurveillance [161].
The latter events are illustrated schematically in Figure 5A. Here the activating mutation (or
epigenetic control) in the stem cell either is neutral (left) or confers a selective advantage for the
SC (right). As shown on the left panel, in the absence of other changes, the self-renewal results in
a SC which does not express the activated oncogene copy, but rather the wild-type allele, whereas
the TA cell does express the activating allele and may either expand or as illustrated for a single
change, suffer intrinsic or extrinsic deletion. However, the SC remains as a pool in the heterozygous
state, which can be subject to further change in a pre-tumor progression [34]. The right panel shows
the state when the activating gene does confer a selective advantage (like ERG in TMPRSS2-ERG
fusions) [162,163]. In this case, the TA cell retains the mutation, can expand and may restore expression
of the mutant gene if RME is truly random, as we suspect (Figure 5B). Hence clones of cells within
the tumor, as seen in many immunohistochemical studies of prostate cancer, could ultimately emerge.
This might also explain the increasing prevalence of “cancer mutations” in apparently normal tissues
adjacent to tumor cells [164].
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Figure 5. Epigenetic control of gene silencing and clonal deletion in prostate cancer development.
(A) Activating mutations (or epigenetic controls) in the stem cell are either neutral (left) or confer
a selective advantage for the SC. As shown on the left panel, in the absence of other changes the
self-renewal results in an SC which does not express the activating copy, but rather the wild-type allele,
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whereas the TA cell does express the activating allele and may either expand or as illustrated for a single
change, suffer intrinsic or extrinsic deletion. However, the SC remain as a pool of the heterozygous
state, which can be subject to further changes during pre-tumor progression. The right panel shows
the outcome when the activating gene does confer a selective advantage (like ERG in (B)). In this case,
the TA cell retains the mutation, can expand and may restore expression of the mutant gene if RME
is truly random, as we propose. (B) Epigenetic/allelic silencing of the TMPRSS2-ERG fusion gene.
After asymmetric division (self-renewal) of the stem cells, the daughter cell population contains but
does not express the fusion, whilst on further mitoses and differentiation the hyper-activated ERG (ETS
transcription factor) gene is even more highly expressed, under androgen stimulation of the TMPRSS2
promoter [54]. This provides a selective growth advantage to ERG+ cells within the tumour mass.
16. Conclusions: A Hypothesis for Epigenetic Control of Epithelial Cell Differentiation in
Human Prostate
There is a prominent role for each of the major epigenetic control mechanisms in prostate epithelial
cell differentiation. Histone modifications and changes to chromatin configuration provide the initial
overall control of transcription and the selection of allelic preferences in gene expression. A cell
stage-specific representation of this is shown in Figure 6. However, as stated earlier, there is a continuum
of phenotypic changes between the defining asymmetric division of SC and the final and terminal
differentiation into luminal cells.
Figure 6. An integrated model of epigenetic control in prostate epithelium. The differentiation of
prostate epithelium is controlled by multiple epigenetic influences. Between the defining self-renewal
upon SC asymmetric cell division and the terminal differentiation into a luminal cell, there exists a
continuum of differentiation (see shaded triangle). TA and CB cells are recognizable intermediates but
exist within this continuum. As cells become more differentiated, the reversibility of the procedure
becomes less likely (see Figure 1B). Details of individual controls are given in the text.
We have defined a set of transcription factors, including the critical Rock 2 kinase, which controls
transcription of non-overlapping gene sets (Tables 1 and 2). These master controllers are co-regulated
not only in the prostate but in other human tissues. Hormonal and growth factors are clearly influential
but act differentially on the individual cell types, for example, retinoids and glucocorticoids in SC,
estrogen receptor in TA/CB cells and androgens in more luminal cells.
The SC state appears to be one of “active” quiescence, where expression at high levels of many
miRNAs, and the existence of bivalent and/or poised chromatin (controlled by simultaneous binding
of repressive and activating modified histones) indicates a cell which can react rapidly to changes in
microenvironment/cell division, to produce a more differentiated daughter cell. Genomic methylation
plays a less important, but not insignificant role, as SC are generally hypomethylated, with only a
few clusters of hypermethylated chromatin. Some of these CpG clusters influence the SC adhesive
properties i.e., sensing changes to the microenvironment, which may define fate after asymmetric
division. However, the patterns of differential CpG methylation between normal and malignant
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cells from the same patient lie out-with the normally screened CpG “islands” can provide significant
information about cellular processes involved in both carcinogenesis and differentiation, particularly if
carried out on a patient-specific basis using matched normal and malignant tissues.
In terms of understanding prostate cancer, and devising more effective and longer-lasting
treatments, we need to consider the phenotype of not only the majority cell population within normal
and malignant prostate epithelium but also minor populations such as progenitors and stem-like cells.
The stem-like cells provide a strong argument in favor of an intrinsic therapy-resistant cell in cancers,
rather than induction of resistance by the therapies. Since the ability to differentiate appears to be
hard-wired- into all such stem-like cells, one solution would be to deplete or eliminate the SC by
inducing differentiation, as shown in acute promyelocytic leukemia where pre-treatment with retinoic
acid results in a more differentiated cell, which can be killed effectively by traditional chemotherapies.
Exploitation of this fundamental property of the resistant stem-like population i.e., a focus
on cellular differentiation in prostate cancer, rather than the traditional description of cancer as a
fast-growing cell, has now yielded three potentially novel strategies to improve treatment efficacy:
1. Treatment with inhibitors of histone deacetylase, (at a concentration about 100-fold lower than
that used in cytotoxic cancer treatments) resulted in a 40% increase in SC radio-sensitivity, whilst
not affecting the more differentiated and radiosensitive cells. The in vitro data strongly promotes
the use of HDAC inhibitors (at sub-toxic doses) as radio-sensitizers in prostate cancer treatments.
2. Radiotherapy (and chemotherapy) patients are often treated with glucocorticoids to counteract
the side-effects of treatment. In our studies of miR99a/100 in primary PCa, pre-treatment
with dexamethasone stimulated miR99a/100, reducing SMARC expression and decreased
radiotherapy responses, whereas combination treatment with the GCR inhibitor Mifepristone
increased radio-sensitivity by stimulating the expression levels of miR-99a/100 and decreasing
SMARC-induced chromatin condensation. Therefore, the clinical use of GCR inhibitors should
clinically enhance radiotherapy and perhaps reduce tumor relapse.
3. Overexpression of exogenous miR-548c-3p, which is highly expressed in PCa SC,
made radiosensitive CB cells more resistant to irradiation, by induction of a more stem-like state.
Thus, inhibition of the SC-preserving activity of high miR-548c-3p levels should also increase
clinical radiotherapy efficacy.
17. Future Perspectives and Challenges
To paraphrase what Waddington so beautifully illustrated almost 80 years ago: by getting stem-like
cells in cancer to roll down into epigenetic valleys, we can perhaps kill more of them by conventional
means. The challenge faced by researchers wishing to translate similar findings into clinical practice is
the similarity between the epigenetic control of normal and malignant cell differentiation. Preservation
of normal stem cell function, not only in the target organ, but elsewhere in the body remains difficult
to predict, and off-target effects may take some time to manifest themselves if affecting slowly cycling
stem cells. A major feature of Waddington’s Hypothesis was the prediction of developmental plasticity
mediated by epigenetic control. Mutational changes to the cancer genome are essentially irreversible
and rather stupid evolutionary strategies and are mainly exploited by prostate cancers as a response to
therapy. A smart tumor cell will maintain its options in a changing tumor microenvironment (Figure 7).
Finally, the data from prostate and other cancers provides insights to be gained from a cell
fractionation approach to complex tissues, prior to deep sequencing or similar analyses, and its
ability to generate genuinely novel targets for cancer therapy. Recent data also clearly indicate the
compromise offered by analysis of established cell lines, which have been selected for their ability to
grow (sometimes more than 40 years ago), compared to tissues. The high quantity, high heterogeneity,
high depth approaches to the analysis of tissues also present problems with interpretation—requiring
large numbers of cells. Rather, current efforts to miniaturize key assays such as genomic methylation,
chromatin immunoprecipitation, and better fidelity DNA/RNA sequencing from single cells are all key
to the study of minor cell populations.
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Figure 7. Epigenetic control of gene silencing and clonal deletion in prostate cancer development.
Epigenetic gene activation/repression allows the activated stem cells in cancer or pre-cancer to revert
to a resistant phenotype when challenged with extrinsic or intrinsic mutant cell deletion whereas
mutational activation cannot be reversed, allowing the cells to be deleted.
With major pharmaceutical companies seemingly focused on generating biosimilar drugs in a
restricted pool of therapeutics, offering life extensions of months and at a high cost in many cases,
relative to either standard of care or placebo treatments, the ability to kill more of the disparate
cell types in a tumor based on epigenetic mechanisms, in a “low mutation” primary cancer such as
prostatic adenocarcinomas.
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